Vial Logo

TL1A

TL1A antibody diagram.
VIAL-TL1A-HLE, a novel, subcutaneous mAb with proprietary half-life extension technology targeting TL1A for a potentially best-in-class treatment for IBD.
  • Preclinical data support the potential for best-in-class dosing interval for patient convenience and efficacy among anti-TL1A therapies
  • A Phase 1 open-label study in Australia will evaluate safety, pharmacokinetics, and pharmacodynamic responses in healthy volunteers
  • Interim subcutaneous safety and pharmacokinetic data from healthy volunteers expected in H2 2025

Key Data

Preclinical data indicate a best-in-class dosing interval for patient convenience and efficacy compared to the first and second-generation anti-TL1A candidates.

Graph showing peripheral venous blood-plasma-concentration dosing simulation
High Potency​

Equal or more potent than competitors based on in vitro assays. Potency in line with first line anti-TL1A mAbs demonstrated by neutralization of apoptosis in TF-1 cells.​

Low Immunogenicity Risk​

Low immunogenicity risk predicted by pre-clinical models.​

Industry Leading Half-Life​

Q9-12M modeled dosing frequency to reduce patient burden. PBPK modeling suggesting industry leading 100+ day predicted half-life.​

Differentiated Product Profile​

VIAL-TL1A-HLE is potentially a best-in-class anti-TL1A mAb with an extended half-life to support Q9-12M dosing, powered by Vial’s HLE platform. The program is also applicable to MASH, Atopic Dermatitis, SSc-ILD, Rheumatoid Arthritis, Hidradenitis Suppurativa, among others.

Get in touch